(629 Kb) -

Atypical rearrangement involving 3′-IGH@ and a breakpoint ... - PMC

Real-world evidence refers to clinical evidence derived from the analysis of , which is collected from sources outside of traditional highly-controlled randomized clinical trials (RCTs). These sources include electronic health records, insurance claims, and product/disease registries. 1. Addressing Gaps in Clinical Trials (629 KB)

Patients with comorbidities like COPD or cardiovascular disease are often ineligible for trials, leaving a gap in data regarding how they will respond to new therapies like immune-checkpoint inhibitors. 2. Rare Molecular Subsets Atypical rearrangement involving 3′-IGH@ and a breakpoint

In cases where randomized trials are impossible due to small patient populations, RWE has been used to supplement single-arm trials for drug approvals. Rare Molecular Subsets In cases where randomized trials

RWE helps researchers identify gaps in how care is delivered geographically or demographically. For instance, data from the Ontario Institute for Clinical Evaluative Sciences (ICES) has shown that older lung cancer patients are statistically less likely to be referred to an oncologist or receive systemic therapy.

The approval and reimbursement of selpercatinib for RET-positive advanced NSCLC was supported by comparing trial data against RWE from databases like Flatiron Health . 3. Evaluating Quality of Care

The reference (kilobytes) is most commonly associated with a specific scholarly review regarding the use of Real-World Evidence (RWE) in the management of lung cancer, published in the journal Current Oncology . Real-World Evidence in Lung Cancer Management